Authored for clinicians with emphasis on evidence-based practice, updated guidelines (AASLD 2018, EASL 2017/2024 updates), and practical decision-making tools.

Epidemiology & Virology Primer (Clinician Refresher)

HBV is a Hepadnaviridae family, enveloped virus with a partially double-stranded, relaxed circular DNA genome. It replicates via an RNA intermediate using a viral reverse transcriptase — a feature conferring high mutagenic potential and underpinning antiviral resistance concerns. Key antigenic components include:

Note: HBV DNA levels can range from undetectable to >10⁹ IU/mL in acute infection. Genotype matters: Genotypes A & D more likely to progress to chronicity; B & C have higher rates of HBeAg seroconversion but may exhibit reactivation later.

Clinical Presentation & Diagnosis: When to Suspect Acute HBV

Epidemiologic Red Flags:

• Recent exposure (e.g., needlestick, unprotected sex, IV drug use, travel to endemic region [Southeast Asia, Sub-Saharan Africa, Amazon basin])
• Perinatal transmission risk (infants of HBsAg+ mothers despite immunoprophylaxis)
• Unexplained hepatitis in patients with negative HEV, HAV, HSV, CMV, EBV, autoimmune markers

Symptoms (Incidence: 30–50% in adults; <10% in children <5 y):

• Prodrome: Flu-like symptoms (fever, myalgia, malaise), nausea/vomiting
• Icteric phase: Jaundice, dark urine, pale stools, RUQ pain/tenderness (hepatomegaly ± splenomegaly)
• Fulminant presentation (<1% of acute cases): Rapid deterioration with encephalopathy, coagulopathy (INR >2.0), ascites, hepatic hydrothorax — mortality up to 80% without transplant

Key Clinical Pearl:

Acute HBV should be considered in any adult with unexplained ALT >5× ULN + bilirubin elevation, even if asymptomatic or minimally symptomatic.
Source: AASLD 2018 Guidance onHBV Prevention, Diagnosis, and Management.

Diagnostic Workup: Serology & Beyond

Essential Initial Testing (Order as Panel)

Confirmatory & Prognostic Testing

1. HBV DNA quantification (qPCR, LOQ ~10–20 IU/mL)
   • Acute HBV: Typically >10⁷ IU/mL during peak viremia; declines over weeks-months
   • Prognostic value: Failure to decline by 8–12 weeks predicts chronicity
2. Liver Function Tests (LFTs):
   • ALT often >1000 U/L (can exceed 5000 U/L); AST usually <ALT; ALP mildly elevated
   • Bilirubin: Direct bilirubin predominates; >3 mg/dL warrants urgent assessment for fulminant hepatitis
3. Coagulation: INR is more sensitive than PT for synthetic dysfunction
4. Ultrasound with Doppler (if decompensation suspected): Assess liver morphology, portal flow, exclude thrombosis

Coinfection Screening (Mandatory in All New Diagnoses)

• HCV RNA (ELISA alone insufficient due to window period)
• HIV antibody/antigen (4th gen assay)
• HDV IgM/IgG + total anti-HDVespecially if:
  • HBsAg+ for >6 months
  • Unusual severity or rapid progression
  • Origin from HDV-endemic regions (Mediterranean, West Africa, Amazon basin)

Evidence: Coinfection increases risk of fulminant hepatitis and cirrhosis (AASLD 2018; J Hepatol 2024 HDV guidelines).

Management: When to Treat & How

Supportive Care (95–98% of Acute HBV Cases)

• Hydration, nutritional support, avoid hepatotoxins (alcohol, unnecessary meds)
• No antivirals in uncomplicated acute hepatitis — may delay immune clearance and select for resistance

Antiviral Therapy Indications (AASLD/EASL Criteria)

Antivirals are indicated only in:

1. Fulminant hepatic failure (FHF):
   • Defined by: INR ≥1.5 + encephalopathy ± ascites in setting of acute hepatitis
   • Start immediately — do not wait for serology confirmation if clinical suspicion high
2. Protracted severe acute hepatitis B (pS-AHB):
   • Persistent bilirubin >3 mg/dL (or direct >1.5 mg/dL) AND INR >1.5 despite supportive care
   • Or progressive synthetic dysfunction (e.g., hypoalbuminemia <3 g/dL, rising creatinine)

First-Line Antivirals (All Nucleos(t)ide Analogues – NUCs):

Critical Notes:

• Do NOT use interferon alpha — contraindicated due to risk of precipitating liver failure and severe flu-like side effects (Hepatology 2019;69:2137–2152).
• Duration of therapy:
  • In FHF/pS-AHB: Continue until sustained HBsAg loss (confirmed ≥6 months apart)
  • If undergo liver transplant: Lifelong NUC therapy (retransplantation often required without suppression)

Monitoring During Antiviral Therapy:

• Weekly: LFTs, INR, bilirubin
• Biweekly:HBV DNA until suppressed (<20 IU/mL)
• Monthly: Clinical assessment for decompensation

Defining Transition to Chronic Infection & Next Steps

Chronic HBV is diagnosed if:
✅ HBsAg persists >6 months after initial diagnosis
(Note: 90% of chronic cases arise from perinatal infection; only 5–10% of immunocompetent adults fail to clear)

Actionable Steps Upon Diagnosis of Chronicity:

1. Repeat full serologic panel (HBsAg, anti-HBs, total anti-HBc, HBeAg, anti-HBe)
2. Baseline HBV DNA, LFTs, liver ultrasound ± FibroScan®/ELF test
3. Assess for HCC screening eligibility (age >40, family HCC history, cirrhosis, high viral load >2000 IU/mL)
4. Refer to hepatology if:
   • ALT persistently elevated + HBV DNA >2000 IU/mL
   • Signs of advanced fibrosis (F3/F4 on elastography/biopsy)
   • HBeAg-negative disease with fluctuating enzymes/DNA

Prevention & Public Health Imperatives

1. Post-Exposure Prophylaxis (PEP):
   • Perinatal: HBV vaccine + HBIG within 12h of birth → 95% efficacy
   • Occupational (needlestick): Unvaccinated → initiate vaccine series + HBIG; vaccinated with unknown Ab status → check anti-HBs; if <10 mIU/mL, give booster ± HBIG
2. Vaccination: All adults ≤60 y (USPSTF Grade B); older adults with risk factors (Grade C)
3. Household/sexual contacts: Test & vaccinate if anti-HBs negative

Evidence Summary Table: Key Practice-changing Data

Final Clinical Pearls:

• The “window period” is real: If HBsAg– but IgM anti-HBc+ with elevated ALT, repeat serology in 2 weeks.
• HBeAg status doesn’t guide acute management — focus on clinical severity and viral kinetics.
• Never assume resolution without confirmatory HBsAg negativity at 6 months.
• Chronicity is preventable: Early antiviral use in pS-AHB may reduce progression to cirrhosis (Hepatology Commun 2022;6:1485–1495).

For full chronic HBV management algorithms, refer to the AASLD 2018 Guidance or EASL Clinical Practice Guidelines: Hepatitis B update (2024). Always consult institutional antiviral resistance protocols when selecting therapy.

— Prepared by Infectious Disease & Hepatology Consult Service — Last updated: June 2024.